-+ 0.00%
-+ 0.00%
-+ 0.00%

Acumen And JCR Pharma Collaborative Study Shows Improved Brain Distribution of AβO-Targeting Antibodies

Benzinga·12/02/2025 13:15:18
Listen to the news

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new research at the 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place December 1-4, 2025, in San Diego and online. Results from a collaborative study with JCR Pharmaceuticals demonstrated improved delivery of AβO-targeting monoclonal antibodies to the central nervous system, including sabirnetug (ACU193), through the blood-brain barrier using the transferrin receptor (TfR) pathway, which is being developed to potentially increase and broaden brain distribution and maximize the efficacy-to-safety ratio. Building on these results, Acumen and JCR Pharmaceuticals are now developing TfR-targeting antibodies for clinical testing. Additionally, results on clinical trial recruitment from the Phase 2 ALTITUDE-AD clinical trial showed that site databases and physician referrals were the most reliable recruitment methods overall.